Jacobs Levy Equity Management Inc. Decreases Position in Kronos Bio, Inc. (NASDAQ:KRON)

Jacobs Levy Equity Management Inc. cut its stake in Kronos Bio, Inc. (NASDAQ:KRON) by 26.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 300,968 shares of the company’s stock after selling 105,796 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Kronos Bio were worth $286,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KRON. Kennedy Capital Management LLC lifted its stake in Kronos Bio by 8.7% in the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock valued at $142,000 after buying an additional 12,007 shares in the last quarter. Gilead Sciences Inc. purchased a new position in Kronos Bio in the 4th quarter valued at about $179,000. Deltec Asset Management LLC purchased a new position in Kronos Bio in the 4th quarter valued at about $190,000. Peapod Lane Capital LLC acquired a new stake in Kronos Bio in the 4th quarter valued at about $534,000. Finally, Renaissance Technologies LLC raised its holdings in Kronos Bio by 19.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,171,808 shares of the company’s stock valued at $1,113,000 after acquiring an additional 192,754 shares during the last quarter. 64.09% of the stock is owned by hedge funds and other institutional investors.

Kronos Bio Trading Down 3.4%

KRON stock opened at $0.68 on Monday. The company has a market cap of $41.53 million, a price-to-earnings ratio of -0.48 and a beta of 1.75. Kronos Bio, Inc. has a 12 month low of $0.65 and a 12 month high of $1.60. The firm has a 50-day moving average of $0.82 and a two-hundred day moving average of $0.91.

Kronos Bio (NASDAQ:KRON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.13). The business had revenue of $2.27 million during the quarter, compared to analyst estimates of $1.00 million. Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. As a group, equities analysts forecast that Kronos Bio, Inc. will post -1.36 earnings per share for the current year.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.